Dexmethylphenidate Hydrochloride
NDC 55466-123
Product Information
Dexmethylphenidate Hydrochloride is a ANDA-approved product labeled by Neolpharma, Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a yellow product. This product entry covers the primary NDC 55466-123 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
BLUE (C48333)
8 MM
NP045;5
NP046;10
Code Structure Chart
Product Details
What is NDC 55466-123?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- DEXMETHYLPHENIDATE HYDROCHLORIDE (UNII: 1678OK0E08)
- DEXMETHYLPHENIDATE (UNII: M32RH9MFGP) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)
- D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)
- SODIUM LAURYL SULFATE (UNII: 368GB5141J)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- FD&C BLUE NO. 2 (UNII: L06K8R7DQK)
* Please review the full disclaimer at the bottom of this page.
Patient Education
Dexmethylphenidate
Dexmethylphenidate is used as part of a treatment program to control symptoms of attention deficit hyperactivity disorder (ADHD; more difficulty focusing, controlling actions, and remaining still or quiet than other people who are the same age) in adults and children. Dexmethylphenidate is in a class of medications called central nervous system (CNS) stimulants. It works by increasing the amounts of certain natural substances in the brain.
[Learn More]
* Please review the full disclaimer at the bottom of this page.